Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


St. Jude Warning Letter Spotlights CAPA Flaws At CardioMEMS Unit

This article was originally published in The Gray Sheet

Executive Summary

The warning letter highlights validation and recordkeeping problems at the Atlanta manufacturing facility for the CardioMEMS heart failure remote monitoring system, but it is not expected to affect device availability.

You may also be interested in...

Warning Letter Roundup & Recap – October 20, 2015

St. Jude Medical's CardioMEMS unit cited for quality system reg violations; complaints weren't evaluated for MDR-reportability at maker of wound dressings and gauze; and more. Two device warning letters were listed by FDA this week.

St. Jude Sees New Techs Keeping It One Step Ahead Of The Field

Improving outcomes, reducing costs, and cutting readmissions are front and center for St. Jude Medical as it moves into new areas of cardio technology that suit the changing needs of both providers and patients.

St. Jude Builds Chronic Pain Business With NeuroTherm Acquisition

NeuroTherm makes devices for radiofrequency ablation of nerves in painful facet joints in the neck or back to treat chronic pain. Although it markets neurostimulators, St. Jude currently does not sell any devices in the radio-frequency ablation segment of the pain-therapy market.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts